We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Soleno Therapeutics Inc | NASDAQ:SLNO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.88 | 6.45% | 47.54 | 44.03 | 55.00 | 48.36 | 44.48 | 44.63 | 433,159 | 01:00:00 |
Presentation Details:Date: Wednesday, November 29Time: 12:00pm Eastern TimeLocation: Lotte New York Palace Hotel, Track 4, Holmes 2 Ballroom
About Soleno Therapeutics, Inc.Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program in early 2018. Soleno, through its wholly-owned subsidiary, Capnia, Inc., continues to market Capnia’s innovative medical device, the CoSense® End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. It is expected that CoSense will be monetized and will not be a focus for the company in the long-term.
For more information, please visit www.soleno.life.
CONTACT:Brian RitchieLifeSci Advisors, LLC212-915-2578
1 Year Soleno Therapeutics Chart |
1 Month Soleno Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions